HCPCS code J9351: Topotecan injection, per 0.1 mg2026 Medicare rate & RVUs in Illinois
Topotecan injection is an intravenous antineoplastic drug reported in 0.1-mg units when administered during cancer treatment.
CMS doesn’t publish an office rate for J9351 in Illinois.
Medicare allowed amount for participating (non-QP) physicians, before deductible, coinsurance and claim adjustments. Not a patient’s bill or a hospital charge.
Your location
On this page 9 sections
What J9351 covers
Topotecan is an injectable cytotoxic drug used to treat cancers including ovarian cancer, small-cell lung cancer, and cervical cancer. Oncology teams administer it by intravenous infusion in outpatient cancer clinics or hospital infusion departments. J9351 identifies the medication; an appropriate chemotherapy-administration code describes the infusion service when it is separately reportable. Select the drug code based on the medication administered, not the cancer diagnosis alone.
CMS assigns J9351 status E, excluding this code from the physician fee schedule. When Medicare covers the drug, it is a Part B drug generally paid using CMS’s quarterly Average Sales Price drug pricing files. Coverage is left to the Medicare contractor’s judgment. One HCPCS unit represents 0.1 mg of topotecan, so report units based on the documented amount administered; for example, 10 mg equals 100 units.
This summary was written with AI assistance from CMS physician fee schedule data and checked against the CMS billing rules shown here. Rates on this page come directly from CMS files.
Where J9351 pays more and less in Illinois
The same RVUs, adjusted for each area’s costs. Open a locality for its calculation, history and nearby areas.
| Payment locality | Office | Facility |
|---|---|---|
| Chicago, IL | Unavailable | Unavailable |
| East St. Louis, IL | Unavailable | Unavailable |
| Rest of Illinois | Unavailable | Unavailable |
| Suburban Chicago, IL | Unavailable | Unavailable |
How the J9351 rate is calculated
Each of J9351’s three RVUs is multiplied by a geographic index (GPCI) for the payment locality, added up, and multiplied by the conversion factor. Drag the indexes or enter a ZIP to see what moves the rate.
How the rate is built · J9351
RVUs × geographic indexes × conversion factor
Work0.00
0.00 RVUs× 1.000 GPCI
Practice expense0.00
0.00 RVUs× 1.000 GPCI
Malpractice0.00
0.00 RVUs× 1.000 GPCI
Adjusted RVUs
0.0000
Conversion factor
$33.4009
Medicare rate
$0.00
Every GPCI starts at 1.000, the national rate. Enter a ZIP or drag a slider.
Payment rules and modifiers for J9351
J9351 has no global surgery period, no multiple-procedure, bilateral or assistant-at-surgery adjustment, and no professional/technical split. What changes the payment is where the service happens: the place of service on the claim decides whether Medicare pays the office or the facility rate.
Place of service · J9351
Which rate does Medicare pay?
The POS code on the claim line (CMS-1500 box 24B).
POS 11 · non-facility rate · national
—
J9351 isn’t priced in this setting.
J9351 compared with similar codes
Compare codes · National
4 codes, side by side
How to choose
- J9352Trabectedin injectionPer 0.1 mg
- J9352 identifies trabectedin, not topotecan. Both codes use a 0.1-mg unit, so confirm which drug was administered.
- J9357ValrubicinPer 200 mg
- J9357 identifies valrubicin. Use J9351 for topotecan rather than selecting by the general fact that both are antineoplastic drugs.
- J9350Mosunetuzumab injectionPer 1 mg
- J9350 identifies mosunetuzumab, a different drug with a 1-mg unit. J9351 is specific to topotecan and uses a 0.1-mg unit.
J9351 billing questions
What does one unit of J9351 represent?
One unit represents 0.1 mg of topotecan. Calculate units from the documented amount administered.
Does status E mean Medicare never covers topotecan?
No. Status E excludes J9351 from the physician fee schedule; when Medicare covers the drug, payment is under another method. Coverage is left to the Medicare contractor’s judgment.
Is the chemotherapy infusion reported with J9351?
J9351 identifies the drug, not the infusion service. An appropriate chemotherapy-administration code, such as 96413 when applicable, describes the infusion work if separately reportable.
How is J9351 distinguished from J9352?
J9351 identifies topotecan, while J9352 identifies trabectedin. Both have a 0.1-mg unit, so select the code for the drug administered.
What documentation supports the units?
Document the topotecan administered and its amount in milligrams. The reported units should reflect 0.1 mg per unit.
Where these rates come from
FeeBase calculates base physician payments from CMS work, practice-expense and malpractice RVUs, adjusted by each locality’s geographic indexes and the conversion factor. Services without a published rate are labeled, never given a made-up amount. Amounts are Medicare allowed amounts before claim adjustments: not a patient’s bill or a commercial rate.
CMS RVU26D · effective Oct 1, 2026 through the day before Jan 1, 2027
Fee sheets · Coming soon
Put J9351 and the rest of your codes on one sheet
Your codes at your locality, with payer contracts beside Medicare.
Join the waitlist